Systemic Failure: What Is Menopause Really?

Menopause and perimenopause are not discrete events, but a continuum of hormonal and metabolic dysfunction. Treating perimenopause (the onset of decline) and menopause (the established state) as separate entities is a fundamental error; they are different stages of the same systemic failure. The conventional narrative focuses on declining estrogen, but this is only one piece of a much larger puzzle. Menopause is, in reality, a coordinated breakdown of five interconnected systems:

1. Growth Hormone (GH) Production Failure: The production of GH by the pituitary gland, crucial for tissue repair, metabolism and vitality, decreases dramatically from age 30 and plummets around age 50.
2. Insulin Resistance: As metabolism slows down, the body becomes less efficient at using energy, leading to insulin resistance, weight gain, inflammation, and increased hormonal imbalance.
3. Cellular Senescence and Inflammation: Aged and damaged cells ("senescent cells") accumulate and release pro-inflammatory signals, acting as "biochemical terrorists" that perpetuate chronic inflammation throughout the body.
4. Neurological Dysregulation: The hypothalamic-pituitary-adrenal (HPA) axis, the body's stress response system, becomes dysregulated, causing cortisol imbalances and increased hormonal dysfunction.
5. Mitochondrial Dysfunction: The power plants of the cells (mitochondria) become inefficient, producing less energy (ATP) and more oxidative "waste," which underlies all other problems.

Hot Flashes Demystified: A Neurological "Blackout"

The most emblematic symptom of menopause, hot flashes, is not a magical event or a "woman's curse." It is a direct thermoregulatory failure caused by a dysfunction in the hypothalamus, the brain's "thermostat." The hypothalamus, which maintains body temperature within a precise range, relies on estrogen signaling for its calibration. When estrogen levels fall, the signal becomes "noisy" and static.

The hypothalamus, desperate to maintain homeostasis, misinterprets these fluctuations as catastrophic overheating and activates an emergency cooling protocol:

• Peripheral Vasodilation: The blood vessels on the surface of the skin dilate massively, releasing heat and causing a burning sensation.
• Tachycardia: The heart pumps faster to move blood to the periphery, causing palpitations.
• Profuse sweating: The sweat glands are activated in an attempt to cool the body by evaporation.

Hot flashes are a neurological "blackout," an error in the body's thermoregulatory system code, triggered by a decline in hormonal signaling.

Conventional Failure: From Mare's Urine to Fairy Dust

The conventional medical and wellness approach to menopause is, to a large extent, a testament to ignorance or indifference to the actual physiology.

Traditional Hormone Replacement Therapy (HRT)

For decades, the primary solution was Premarin, a drug derived from the urine of pregnant mares. This approach is not only biologically incongruous but has also been linked to an increased risk of certain cancers. The idea that the solution to a complex human endocrine event lies in horse urine exemplifies the arrogance of a system that ignores the precision of human biology.

The Supplement Market

The menopause supplement market is a "carnival of fraud." Products like black cohosh, evening primrose oil, or "miracle berries" from the Amazon are sold with the promise of relief. However, these substances are not the correct "keys" for your body's "locks" (receptors). They are like "pocket lint" that may bump against the lock but will never open it. They cannot replicate the precise biochemical instructions of an actual hormone. Relying on them is an act of intellectual surrender and a voluntary tax on hope.

The Reboot Protocol: A Multivector Assault

The goal of an advanced protocol is not simply to replace estrogen, but to restore the integrity of whole-body signaling. It's about resetting the hypothalamus, resensitizing the endocrine system, and allowing the body to once again play the symphony of its own youth. This requires a multifaceted approach that addresses the five pillars of menopausal dysfunction.

Phase 1: Rebooting the "Conductor of the Orchestra" (Hypothalamus and Pituitary Gland)

The first step is to "wake up" the driver of the system, the hypothalamic-pituitary axis, which has fallen "asleep".

• CJC-1295 with DAC and Ipamorelin: This peptide combination signals the pituitary gland to resume producing youthful pulses of growth hormone (GH). CJC-1295 establishes an elevated baseline, while Ipamorelin induces clean, rhythmic peaks, mimicking the natural production of a younger person. This is critical for tissue repair and metabolism.
• Kisspeptin: It is the master regulator of the gonadal axis. It acts directly on the hypothalamus, stimulating the release of GnRH (gonadotropin-releasing hormone), which is the fundamental trigger of the entire reproductive hormone cascade. It's like pressing the "reset" button at the core of the system that has shut down.

Phase 2: Repairing the Metabolic "Engine" (Insulin Sensitivity)

A hormonal system cannot function properly in an environment of insulin resistance. It's like having a flooded engine.

• Retatrutide: This peptide is the "metabolic hammer." As a triple agonist, it regulates blood sugar, crushes insulin resistance, and resensitizes the entire metabolic system. It is crucial because insulin dysfunction is one of the main amplifiers of menopausal symptoms.
• Cardarine: A metabolic catalyst that activates the PPAR-delta receptor, instructing muscles to burn fat as their preferred fuel. This increases endurance and reverses mitochondrial inefficiency, creating a more powerful and efficient engine.

Phase 3: Systemic Repair and Inflammation Control

While the engine is being restarted, it is vital to repair the damage accumulated from years of dysfunction.

• BPC-157 and TB-500: The "dynamic duo" of healing. BPC-157 reduces systemic inflammation and repairs soft tissues, including the intestinal lining. TB-500 regulates cellular repair and promotes the healing of microtrauma throughout the body.
• GHK-Cu (Copper Peptide): This peptide modulates over 4,000 genes, restoring them to a more youthful and healthy state of expression. It promotes collagen synthesis, reduces inflammation, and acts as an antioxidant, providing a systemic "software update."

Phase 4: Optimization of Neurology and Sleep

You can't fix the body without fixing sleep, the main window for hormonal and neurological repair.

• DSIP (Delta Sleep-Inducing Peptide): This naturally occurring peptide is not a sedative, but rather an inducer of slow-wave (delta) sleep, the most restorative phase. It is essential for hormonal recovery, as it addresses the hypothalamic dysregulation that causes insomnia.
• Epitalon: This tetrapeptide rejuvenates the pineal gland, resets circadian rhythms, and protects DNA telomeres. It helps mitigate cellular senescence and inflammation, two of the cornerstones of menopausal dysfunction.
• Methylene Blue: A powerful cognitive enhancer that optimizes mitochondrial function in the brain, improving energy production and acting as an antioxidant. It combats brain fog and supports clarity.

Phase 5: Androgen Restoration and Foundational Support

This phase focuses on restarting native hormone production and providing the energy building blocks.

• Enclomiphene: A SERM (Selective Estrogen Receptor Modulator) that tricks the pituitary gland into thinking estrogen levels are low, prompting it to release more LH and FSH. This stimulates the ovaries and adrenal glands to produce more of their own native hormones, including testosterone, which is crucial for energy, libido, and muscle mass in women.
• NMN and NAD+: NMN is the direct precursor of NAD+, the essential coenzyme for all energy transactions in every cell. Supplementing with NMN is like giving new batteries to the 30 trillion cells in your body.
• 5-amino-1MQ: This compound inhibits the NNMT enzyme, which degrades NAD+. By blocking this enzyme, it traps NAD+ inside the cell, increasing its bioavailability and boosting energy production and fat burning.

Total Synergy: How the Protocol Works Together

The power of this protocol lies in its synergistic and coordinated approach. **Kisspeptin** and **Enclomiphene** reset the HPG axis from the hypothalamus and pituitary gland. **CJC/Ipamorelin** restores GH pulses. **Retatrutide** and **Cardarine** repair the metabolic engine. **BPC, TB-500, and GHK-Cu** repair the chassis. **DSIP and Epitalon** optimize sleep and circadian rhythms. And **Methylene Blue, NMN, and 5-amino-1MQ** provide the high-octane energy to power the entire system. It's a complete biological restoration.

The Essential Protocol: The High-Impact Starting Point

For those seeking a high-impact starting point, an essential protocol that addresses 80% of the problem could include five key compounds:

1. Ipamorelin: To restore GH pulses, the basis of repair.
2. BPC-157: To combat systemic inflammation and leaky gut.
3. DSIP: To fix sleep, which is non-negotiable for hormonal health.
4. Enclomiphene: To reactivate native hormone production.
5. Kisspeptin: The strategic system reset that facilitates the action of the other compounds.

Dosage Protocols by Phase: Hormonal and Metabolic Reset in Menopause

IMPORTANT: General Usage Considerations

This protocol is designed to be implemented progressively and in a personalized manner. Not all compounds should be started simultaneously. A stepwise approach is recommended, beginning with the fundamental phases (Phase 1 and Phase 2) and gradually adding the components of subsequent phases according to individual response and specific goals. The duration of each phase is a guideline and should be adjusted according to the evolution of symptomatic markers and, where possible, biochemical markers. This protocol represents an advanced approach to biooptimization that complements, but does not replace, assessment and monitoring by qualified healthcare professionals.

PHASE 1: Reset of the Hypothalamic-Pituitary Axis

Ipamorelin

• Dosage : For the stimulation of physiological growth hormone pulses in the context of menopausal hormone restoration, it is recommended to start with a conservative dose of 200 mcg per administration. This dose may be gradually increased to 300 mcg per administration after 2–4 weeks of tolerance assessment if a more robust effect on body composition and tissue recovery is desired. Users with prior experience with GH secretagogue peptides may consider doses in the 250–300 mcg range from the outset, although the conservative approach is generally preferred to minimize initial adaptation effects such as transient water retention or increased insulin sensitivity.

• Administration Frequency : Administration should be by subcutaneous injection, preferably into abdominal or thigh adipose tissue, in a pattern that mimics the natural GH pulses that occur during sleep and in response to fasting. The optimal protocol includes two daily administrations: the first dose approximately 30–45 minutes before breakfast in a fasted state (taking advantage of the morning glucose nadir to maximize GH release), and the second dose 30–45 minutes before bedtime, ideally at least 2–3 hours after the last meal of the day. For users practicing intermittent fasting, an optional third dose can be administered in the mid-afternoon during the fasting window to synergistically take advantage of low insulin levels. Administration in a fasted state is critical, as elevated glucose or insulin levels significantly suppress secretagogue-induced GH release.

• Cycle Duration : Ipamorelin can be used continuously for extended cycles of 12–16 weeks as an initial restoration phase, allowing sufficient time for the effects on body composition, sleep quality, and recovery markers to fully manifest. Following this initial cycle, a 4–6 week break is recommended to prevent ghrelin receptor desensitization and maintain endogenous GH axis responsiveness. During the break, natural GH production may recover to enhanced levels compared to the pre-intervention state due to upregulation effects that can occur during periods of abstinence after consistent use. After the break, the protocol can be restarted with the expectation of maintaining sensitivity. For users seeking long-term, sustained benefits, a pattern of 12 weeks of active use followed by 4 weeks of rest can be established and maintained for multiple iterations with dose adjustments based on response.

CJC-1295 with DAC

• Dosage : To establish a sustained basal elevation of growth hormone to complement the acute pulses induced by Ipamorelin, a dose of 1-2 mg administered once weekly is recommended. The variant with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days, allowing for this reduced administration frequency. Users new to peptide supplementation should start with 1 mg weekly for the first 4 weeks to assess tolerance and response, with the option to increase to 1.5-2 mg if more pronounced effects on anabolic and recovery markers are desired. The 2 mg weekly dose represents the upper end of the range used in biooptimization protocols and should be reserved for users with documented experience and specific goals of aggressive body recomposition.

• Administration Frequency : Administration is by subcutaneous injection once a week, preferably on the same day of the week to maintain consistent circulating levels. The specific day of administration is less critical than with Ipamorelin, as CJC-1295 DAC establishes a plateau of elevated GH that persists throughout the week. However, many users prefer to administer it on a weekend evening to align any transient effects of the injection (such as mild water retention or initial fatigue) with days of lower work demands. The injection should be administered using a rotational injection site to minimize local irritation, alternating between the abdomen, thighs, and gluteal region. Since this peptide is administered only once a week, it may be convenient to temporarily combine it with the nighttime dose of Ipamorelin on the selected day, although some users prefer to separate all injections to monitor individual responses.

• Cycle Length : CJC-1295 DAC can be used continuously for 8-12 week cycles, although some protocols extend this to 16 weeks when combined with Ipamorelin in a coordinated stack. After the active cycle, a 4-8 week break is recommended to allow the hypothalamic-pituitary axis to recover its baseline sensitivity and to prevent adaptive suppression of endogenous GHRH production. During the CJC-1295 DAC break, Ipamorelin can be continued alone at a reduced dose, or both peptides can be discontinued simultaneously for a more complete "reset." The decision depends on individual goals and observed response. For long-term maintenance protocols after the initial restoration, some users implement 8-week active cycles followed by 4 weeks off, which can be repeated indefinitely with monitoring of relevant health markers such as IGF-1, fasting glucose, and thyroid function.

Kisspeptin-10

• Dosage : As a master regulator of the reproductive axis, Kisspeptin-10 is used at doses that have been explored in clinical research for GnRH stimulation and the subsequent gonadal cascade. For HPG axis reset in the context of menopausal transition, a dose of 1–3 mcg per kilogram of body weight per administration is recommended, which for a 70 kg woman would translate to approximately 70–210 mcg per dose. Most protocols use a conservative range of 100–150 mcg as the standard dose, providing significant stimulation without overactivation. Doses above 300 mcg per administration are rarely warranted and may result in more rapid desensitization of Kiss1R receptors in the hypothalamus. The approach should be to start at the lower end of the range and titrate upward only if the symptomatic response is insufficient after 4–6 weeks of consistent use.

• Administration Frequency : Kisspeptin-10 is administered by subcutaneous injection, typically once daily in the initial phases of the protocol. The optimal timing is early morning, approximately 30–60 minutes before breakfast, to take advantage of the natural circadian nadir of estrogen and create a window of stimulation where the HPG axis is most receptive to activation signals. Some advanced protocols use twice-daily administration (morning and evening) during the first 2–4 weeks as a "loading" phase to maximize axis reset, subsequently reducing to once daily for maintenance. Administration should ideally be coordinated with the Ipamorelin protocol to create synergies between GH axis restoration and gonadal axis restoration, although they can be administered at separate times of day. Consistency in administration timing is important to maintain appropriate rhythmic signaling to the hypothalamus.

• Cycle Duration : Kisspeptin-10 can be used continuously for 8-12 week cycles as an initial HPG axis reset phase. This period allows sufficient time for signaling to the hypothalamus to be restored and for improvement in symptomatic markers such as reduced hot flashes, improved libido, and mood stabilization to be observed. After the initial cycle, a 4-6 week break is recommended to assess whether the axis has regained improved endogenous function. During the break, many users report that the benefits persist partially due to the "recalibration" that has occurred in the axis's sensitivity. If symptoms return significantly during the break, a second cycle may be indicated, although ideally of a shorter duration (6-8 weeks), before the next break. For very long-term use, some protocols consider intermittent administration where Kisspeptin is used 5 days a week with 2 days off, or in cycles of 2-3 active weeks followed by 1 week off, although the evidence for these patterns is more limited.

PHASE 2: Metabolic Engine Repair

Retatrutida

• Dosage : As a triple GIP/GLP-1/glucagon receptor agonist, retatrutide is one of the most potent compounds for restoring insulin sensitivity and optimizing metabolism. It is recommended to start with a very conservative dose of 2–4 mg administered once weekly for the first 4 weeks to allow for gastrointestinal adaptation and assessment of tolerance. Titration should be gradual: after 4 weeks at 2–4 mg, increase to 4–6 mg weekly if tolerance is excellent and more robust effects on glucose and lipid metabolism are desired. More aggressive protocols explored in research use up to 8–12 mg weekly, but this dosage should be reserved exclusively for users with fully established tolerance and specific therapeutic goals of reversing severe insulin resistance, always under close monitoring of metabolic markers and pancreatic function.

• Frequency of administration : Retatrutide is administered by subcutaneous injection once a week, preferably on the same day each week to maintain stable plasma levels. Because this compound has significant effects on gastrointestinal motility and can cause transient nausea, particularly during the initial titration phase, many users prefer to administer it on Friday or Saturday night so that any adverse gastrointestinal effects occur over the weekend when there is greater flexibility. Administration should be performed regardless of meals, although taking it after a light meal may reduce nausea in sensitive users. It is crucial to rotate injection sites weekly between the abdomen, thighs, and gluteal region to minimize local irritation and optimize absorption. Administration can be coordinated with the weekly dose of CJC-1295 DAC if both are being used, although they should be injected at different anatomical sites.

• Cycle duration : Retatrutide can be used continuously for extended cycles of 12–16 weeks, during which the most significant improvements in markers of insulin sensitivity, body composition, and lipid profile are observed. Some protocols extend this to 20–24 weeks when pursuing substantial body recomposition or reversal of established insulin resistance. After the active cycle, a gradual taper period is recommended, where the dose is reduced in 50% increments every 2 weeks before complete discontinuation, to minimize the metabolic rebound that can occur with abrupt discontinuation of incretin agonists. During this taper period and the subsequent 4–8 week break, it is critical to maintain strict adherence to dietary patterns that preserve the achieved insulin sensitivity (low consumption of refined carbohydrates, intermittent fasting, adequate protein intake). After the break, if metabolic markers have stabilized within optimal ranges, restarting may not be necessary. If there is regression, a second cycle at maintenance doses (4-6 mg weekly) can be implemented.

Cardarine (GW501516)

• Dosage : For optimization of fatty acid metabolism and improvement of mitochondrial function through activation of the PPAR-delta receptor, a daily dose of 10-20 mg is recommended. Users new to PPAR modulators should start with 10 mg daily for the first 2 weeks to assess response and tolerance, with the option to increase to 15-20 mg if more pronounced effects on physical endurance and fat oxidation are desired. Doses above 20 mg daily have not demonstrated proportionate benefits in most contexts and may unnecessarily increase the burden on hepatic detoxification systems. The 20 mg daily dose is considered the "sweet spot" where benefits are maximized with a minimal side effect profile for most users.

• Frequency of administration : Cardarine is administered orally in capsule or liquid solution form, with a half-life of approximately 16–24 hours, allowing for once-daily administration. The optimal timing depends on the intended use: to maximize effects on physical performance and endurance during workouts, taking the full 10–20 mg dose approximately 45–60 minutes before exercise is the preferred strategy. For users focused on general metabolic optimization without structured training, morning administration with breakfast provides elevated levels during peak activity and energy expenditure. Alternatively, the dose can be divided into two 10 mg administrations (morning and evening) to maintain more stable levels, although most users find a single daily dose sufficient and more convenient. Administration with fatty foods may enhance the absorption of this lipophilic compound.

• Cycle duration : Cardarine can be used continuously for 8-12 week cycles, during which significant improvements are observed in markers of aerobic endurance, body composition, and lipid profile (particularly increased HDL and reduced triglycerides). After the active cycle, a break of at least 4 weeks is recommended to allow the PPAR-delta signaling systems to return to baseline sensitivity. During the break, the benefits on mitochondrial oxidative capacity tend to persist partially due to structural adaptations that have occurred in skeletal muscle. For users incorporating Cardarine into long-term fitness or body recomposition protocols, an 8-week active cycle followed by a 4-week break can be implemented and repeated with the expectation of maintaining cumulative benefits. It is important to note that the safety of very long-term use (more than 6-12 cumulative months) has not been thoroughly characterized in humans, so protocols that exceed this period should be implemented with caution and regular monitoring of liver function and cardiovascular health markers.

PHASE 3: Systemic Repair and Inflammatory Control

BPC-157

• Dosage : For the goals of reducing systemic inflammation, repairing intestinal permeability, and healing soft tissues in the context of menopausal hormone replacement, a dose of 250–500 mcg per administration is recommended. The 250 mcg dose is appropriate for general maintenance and prevention, while 500 mcg is reserved for more intensive repair phases or when there are specific symptoms of leaky gut, joint pain, or established chronic inflammation. Some protocols use higher doses of up to 750–1000 mcg for specific acute injuries or severe inflammation; however, for the objectives of this menopausal protocol, the 250–500 mcg range is generally sufficient and provides an excellent balance between efficacy and cost-effectiveness.

• Administration Frequency : BPC-157 is administered by subcutaneous or intramuscular injection, typically once to twice daily. For intestinal repair and systemic inflammation reduction, subcutaneous administration in the abdominal area is preferred due to its convenience and proximity to the gastrointestinal tract. Administration can be performed once daily (preferably in the morning on an empty stomach) at a dose of 500 mcg, or divided into two 250 mcg doses (morning and evening) to maintain more consistent levels. Although BPC-157 has systemic properties that do not require local injection at the injury site for most of its effects, if specific joint pain or soft tissue injury is present, administration in proximity to the affected area may provide additional localized benefit. Administration can be coordinated with other peptides in the protocol, although a separate syringe and different injection site should be used for each compound.

• Cycle Duration : BPC-157 can be used continuously for 4-8 week cycles as an initial intensive repair phase, particularly focused on restoring intestinal barrier integrity and reducing systemic inflammation that amplifies menopausal symptoms. Following this initial cycle, many users experience sustained benefits that persist for weeks or months due to genuine tissue repair. If longer use is required, an 8-week active cycle followed by a 4-week rest cycle can be implemented, although BPC-157 has demonstrated an excellent safety profile even with more extended use. For long-term maintenance after the initial repair phase, intermittent use for 4-6 weeks every 3-6 months, or continuous use at a reduced dose of 250 mcg daily, may be considered. The decision should be based on the persistence of inflammatory symptoms and intestinal permeability markers, if available.

TB-500 (Thymosin Beta-4)

• Dosage : To promote systemic tissue repair, modulation of inflammation, and healing of accumulated microtrauma, a dose of 2–2.5 mg administered twice weekly during an initial loading phase is recommended, followed by a maintenance dose of 2–2.5 mg once weekly. The more frequent loading phase during the first 4–6 weeks saturates the tissues with TB-500 and establishes a baseline for regenerative effects, while the subsequent maintenance phase preserves these effects with less frequent administration. Some protocols use higher doses of up to 5 mg per administration, although this generally does not provide proportionate benefits and significantly increases the cost without a clear improvement in outcomes.

• Administration Frequency : TB-500 is administered by subcutaneous or intramuscular injection, with flexibility in the injection site since its effects are systemic. During the initial loading phase (first 4-6 weeks), administer 2-2.5 mg twice weekly, typically separated by 3-4 days (e.g., Monday and Thursday, or Tuesday and Friday) to maintain relatively stable levels. After the loading phase, the frequency is reduced to once weekly for maintenance. TB-500 can be administered at any time of day, regardless of meals, although many users prefer to coordinate it with other peptides that require injection to consolidate all administrations into specific sessions during the week. If both BPC-157 and TB-500 are being used, they can be administered in the same injection session but at different anatomical sites using separate syringes.

• Cycle Length : The full TB-500 protocol typically spans 8–12 weeks of continuous use (including both the loading and maintenance phases), during which significant benefits are observed in the recovery from chronic injuries, reduction of systemic inflammation, and improvement in connective tissue function. After this cycle, a break of at least 4–8 weeks is recommended before considering a second cycle, although the benefits of TB-500 tend to be long-lasting due to the genuine tissue repair it facilitates. For users with specific injury recovery goals or established chronic inflammation, a second cycle after the break may be warranted. For very long-term maintenance, some protocols involve intermittent administration of 2–2.5 mg once per week for 4 weeks every 3–6 months, although the need for this should be assessed individually based on specific symptoms and goals.

GHK-Cu (Copper Peptide)

• Dosage : For modulation of gene expression toward more youthful profiles, promotion of collagen synthesis, and systemic antioxidant effects, a dose of 1–2 mg per administration is recommended. A dose of 1 mg is appropriate for general maintenance and systemic anti-aging goals, while 2 mg is used when seeking more pronounced effects on skin repair, connective tissue density, or inflammation modulation. Some protocols explore higher doses of up to 3–5 mg, particularly when administered intravenously in clinical settings, although for subcutaneous administration in self-application protocols, the 1–2 mg range is generally optimal.

• Administration Frequency : GHK-Cu is administered by subcutaneous injection, typically once daily or every other day depending on the goals and individual response. For intensive repair goals during the first 4–8 weeks, daily administration of 1–2 mg is preferred. After this initial phase, the frequency can be reduced to every other day or even three times per week for maintenance. Administration can be performed at any time of day, although many users prefer nighttime before bed to take advantage of the nighttime repair window. GHK-Cu can also be applied topically to specific areas of skin concern (although this requires special formulations designed for transdermal penetration), but for the systemic goals of this menopausal protocol, the subcutaneous route is preferred due to its bioavailability and widespread effects.

• Cycle Duration : GHK-Cu can be used continuously for 8-12 week cycles as an initial gene modulation and systemic repair phase. After this period, a 4-6 week break is recommended to assess sustained changes in markers of skin health, inflammation, and overall well-being. The effects of GHK-Cu on gene expression and connective tissue structure tend to be cumulative and partially persistent after discontinuation due to structural modifications that have occurred in the tissues. For long-term maintenance, a pattern of 8 weeks of active use followed by 4 weeks of rest, or intermittent use of 4-6 weeks every 3-4 months, can be implemented. The decision should be based on specific goals: users focused on intensive skin repair may prefer more frequent cycles, while those using GHK-Cu as part of a broader anti-aging strategy may opt for less frequent cycles.

PHASE 4: Neurological and Sleep Optimization

DSIP (Delta Sleep-Inducing Peptide)

• Dosage : For induction of deep slow-wave (delta) sleep and restoration of sleep architecture in the context of insomnia associated with menopausal hypothalamic dysregulation, a dose of 100–300 mcg per nightly administration is recommended. Most users find that 200 mcg is the optimum dose that provides significant improvement in sleep quality without residual morning effects. Particularly sensitive users or those new to sleep-inducing peptides may start with 100 mcg to assess response, while those with established severe insomnia may require up to 300 mcg. Doses above 500 mcg rarely provide additional benefit and may result in residual morning sleepiness or more rapid tolerance.

• Frequency of administration : DSIP is administered by subcutaneous or intranasal injection (if an appropriate formulation for this route is available) once daily, approximately 30–60 minutes before the planned bedtime. Subcutaneous administration in the abdominal or thigh area is the most common and provides reliable bioavailability. Timing is critical: administering too early may result in drowsiness before completing nighttime routines, while administering right before bedtime may not allow enough time for the effects to fully develop. The 30–60 minute window before bedtime is generally optimal. DSIP should be part of a comprehensive sleep hygiene routine that includes total darkness in the bedroom, a cool temperature, and avoiding screens for at least one hour before bedtime to maximize its effects.

• Cycle duration : DSIP can be used continuously for 4-8 week cycles as an intensive sleep architecture restoration phase. During this period, many users experience not only improved ease of falling asleep but also improved objective sleep quality, with more time spent in deep sleep stages and fewer nighttime awakenings. After the initial cycle, a 2-4 week break is recommended to assess whether sleep regulation has stabilized sustainably. If sleep quality remains optimal during the break, a second immediate cycle may not be necessary. If regression occurs, an intermittent use pattern can be implemented where DSIP is used 5 nights per week with 2 nights off, or in cycles of 4 weeks of active use followed by 2 weeks of rest. For severe chronic insomnia, some users require longer use, ideally with weekly rest days incorporated to prevent the development of tolerance.

Epitalon

• Dosage : For pineal gland rejuvenation, circadian rhythm reset, and telomere protection, a dose of 5–10 mg per administration is recommended. The most common protocol uses 10 mg administered over a period of 10–20 consecutive days as an intensive cycle of circadian and cellular “reprogramming.” Some protocols use higher doses of up to 20 mg per administration, particularly when pursuing more aggressive telomere modulation goals, although for the purposes of this menopausal protocol focused on sleep optimization and cellular senescence reduction, the 10 mg dose is generally sufficient.

• Administration Frequency : Epitalon is administered by subcutaneous injection once daily, preferably at night approximately 1–2 hours before bedtime, for a concentrated period of 10–20 consecutive days. This “intensive cycle” protocol followed by extended breaks is distinctive of Epitalon and differs from other peptides that are used more continuously. Nighttime administration synergistically takes advantage of the natural circadian repair window and may potentiate the effects of other compounds in the protocol, such as DSIP. Although Epitalon can be administered at any subcutaneous site, many users prefer the abdominal area for convenience and low sensitivity. During the 10–20 days of the active cycle, consistency in administration timing is important to maintain appropriate rhythmic signaling to the pineal gland.

• Cycle Duration : The typical Epitalon protocol consists of an intensive 10-20 consecutive days of daily administration, followed by an extended 4-6 month break before considering repeating the cycle. This "intensive pulse" followed by extended break structure is based on the theory that Epitalon induces lasting changes in pineal gland function and telomere protection that persist long after the peptide has been cleared from the system. Some protocols consider shorter 10-day cycles repeated every 2-3 months, although evidence for this increased frequency is more limited. For users incorporating Epitalon into very long-term anti-aging strategies, a pattern of 20-day cycles performed twice a year (e.g., at the beginning of spring and autumn) may be a reasonable approach that balances potential benefits with caution against overuse of a compound whose very long-term effects have not been fully characterized.

Methylene Blue

• Dosage : For optimization of brain mitochondrial function, improvement of cognitive clarity, and antioxidant effects that combat the "brain fog" associated with the menopausal transition, a dose of 0.5–4 mg per kilogram of body weight per day is recommended. For a 70 kg woman, this translates to a range of 35–280 mg daily. Most protocols use the lower end of this range: 0.5–1 mg/kg (35–70 mg for 70 kg) is appropriate for general cognitive enhancement and mitochondrial optimization, while higher doses of 2–4 mg/kg are reserved for more intensive neuroprotective goals or in the presence of established cognitive dysfunction. It is crucial to start at the lowest end (0.5 mg/kg or approximately 35-40 mg) and gradually titrate upwards according to tolerance and response, as excessive doses can cause adverse effects including nausea, headache, or blue discoloration of the urine (the latter is benign but can be alarming).

• Frequency of administration : Methylene Blue is administered orally as a diluted liquid solution or capsules, typically once daily in the morning with breakfast. Morning administration is preferred because Methylene Blue can have activating effects on cognitive function and mental energy that are most beneficial during waking hours. Taking it too late in the day may interfere with sleep onset in sensitive users. The dose may be divided into two administrations (morning and midday) if using the higher end of the dosage range, although a single morning administration is generally sufficient and more convenient. It is important to take Methylene Blue with food to minimize potential gastrointestinal discomfort and improve tolerance. Plenty of water should be drunk throughout the day when using Methylene Blue, as it is excreted by the kidneys, and adequate hydration facilitates its elimination.

• Cycle Length : Methylene Blue can be used continuously for 4-8 week cycles as an initial cognitive and mitochondrial optimization phase, during which improvements in mental clarity, processing speed, and resistance to cognitive fatigue are observed. After this cycle, a 2-4 week break is recommended to prevent over-adaptation and to assess whether the benefits persist sustainably due to any structural mitochondrial improvements that may have developed. For long-term use, a cycle pattern of 6-8 weeks of active use followed by 2-4 weeks of rest, or intermittent use of 5 days per week with 2 days off per week, can be implemented. Some users utilize Methylene Blue more sporadically, reserving it for periods of particularly high cognitive demand or when they experience more pronounced "brain fog." It is important to note that Methylene Blue has potential interactions with certain medications, particularly selective serotonin reuptake inhibitors (SSRIs), where it may increase the risk of serotonin syndrome, so users taking psychotropic medication should exercise particular caution.

PHASE 5: Androgenic Restoration and Fundamental Energy Support

Enclomiphene

• Dosage : As a selective estrogen receptor modulator that tricks the pituitary gland into stimulating endogenous production of gonadal hormones, including testosterone, a dosage of 12.5–25 mg administered every other day or 3–4 times per week is recommended. The 12.5 mg every-other-day dosage is appropriate as a starting point for most users, providing significant stimulation of the HPG axis without overactivation. For users seeking more pronounced effects on libido, energy, and body composition, the dosage may be increased to 25 mg every other day after 2–4 weeks of evaluating response to the lower dose. Daily administration is not typically necessary or recommended due to the relatively long half-life of enclomiphene, and alternate-day use helps avoid desensitization of the HPG axis.

• Frequency of administration : Enclomiphene is administered orally in capsule or tablet form, on alternate days (Monday-Wednesday-Friday-Sunday, etc.) or on a fixed 3-4 day-per-week schedule. Administration can be at any time of day, although many users prefer the morning to maintain consistency with other morning supplements. It can be taken with or without food, although taking it with food may improve gastrointestinal tolerance in sensitive users. Maintaining a consistent dosing schedule is important to provide appropriate rhythmic stimulation of the HPG axis without causing excessive fluctuations in hormone levels. Alternate-day dosing also allows the pituitary receptors to maintain optimal sensitivity to enclomiphene signaling.

• Cycle duration : Enclomiphene can be used continuously for 8-12 week cycles as an initial stimulation phase of endogenous hormone production. During this period, it is ideal to monitor hormone markers, if possible (LH, FSH, total and free testosterone, estradiol), to confirm that the axis is responding appropriately and that hormone levels are rising toward more youthful ranges without exceeding healthy upper limits. After the initial cycle, a 4-8 week break is recommended to assess whether endogenous hormone production has "reset" to an improved level that is maintained even without enclomiphene stimulation. If symptoms return during the break (reduced libido, fatigue, loss of motivation), a second cycle may be indicated. For very long-term use, some protocols consider patterns of 8-12 active weeks followed by 4-6 weeks of rest that can be repeated, although the ideal goal is that after one or two cycles, the HPG axis has recovered enough function to maintain improved hormone levels without the need for continuous stimulation.

NMN (Nicotinamide Mononucleotide)

• Dosage : As a direct precursor of NAD+, the essential coenzyme for cellular energy metabolism, a daily dose of 250-1000 mg of NMN is recommended. The 250-500 mg dose is appropriate for general maintenance and basal metabolic optimization, while the 500-1000 mg dose is used when seeking more pronounced effects on energy production, mitochondrial function, and sirtuin activation (proteins associated with longevity). Users new to NAD+ precursor supplementation should start with 250 mg daily for the first 1-2 weeks to assess tolerance, with the option to gradually increase the dose based on response. Doses above 1000 mg daily have been explored in research but do not necessarily provide proportionate benefits for most users and significantly increase the cost.

• Frequency of administration : NMN is administered orally and is available in capsule, tablet, or sublingual powder form. Due to its relatively short half-life of approximately 2–4 hours in circulation before being converted to NAD+, many users choose to split the total daily dose into two administrations: one early in the morning with breakfast and another at midday or early afternoon. This strategy maintains more stable NAD+ levels throughout the day compared to a single large dose. Alternatively, taking the entire dose in the morning may be sufficient for many users and is more convenient. Sublingual administration (when using powder) may provide faster absorption and potentially better bioavailability compared to capsules, which require digestion, although both forms are effective. NMN should preferably be taken on an empty stomach or at least 30 minutes before meals to optimize absorption, although it can be taken with food if gastrointestinal discomfort is experienced.

• Cycle Duration : NMN can be used continuously for extended periods without the need for cycling or breaks, as it is a naturally occurring compound that simply replenishes an essential cofactor that declines with age. Many users incorporate it into their indefinite daily supplementation regimen. To assess its effects, it is recommended to use NMN consistently for at least 4-8 weeks, during which time improvements in energy, fatigue resistance, mental clarity, and recovery may be observed. The benefits of NMN tend to be more pronounced when combined with other protocol components that require increased NAD+ for optimal function, such as sirtuin activation induced by calorie restriction or exercise. Some users implement occasional 1-2 week "vacations" from NMN every 3-6 months simply to assess its effect by contrast with its absence, although this is not necessary from a safety or effectiveness perspective.

NAD+ Injectable

• Dosage : For rapid and significant elevation of NAD+ levels via direct administration rather than through oral precursors, a dose of 50–250 mg per administration is recommended. A dose of 100–150 mg is typically used in energy optimization protocols and can provide noticeable effects on energy, mental clarity, and mitochondrial function. Higher doses of 200–250 mg are reserved for intensive detoxification protocols, recovery from severe fatigue, or situations where more robust neuroprotective effects are desired. It is important to note that intravenous administration of NAD+ should be slow (typically over 1–2 hours for doses of 250 mg or higher) to minimize adverse effects such as nausea, anxiety, or chest discomfort that can occur with too rapid an infusion.

• Frequency of administration : Injectable NAD+ is typically administered intravenously in clinical settings or via intramuscular or subcutaneous injection for self-administration. The frequency varies depending on the objective and protocol: for an initial "loading" phase, it may be administered 2–3 times per week for 2–4 weeks to saturate cellular systems with NAD+. After this phase, the frequency may be reduced to once per week or even less frequently for maintenance. Some protocols use injectable NAD+ more sporadically, reserving it for periods of increased demand or significant fatigue. Intramuscular administration (typically into the deltoid or gluteal muscle) is more practical for self-administration than intravenous administration and may provide a more gradual release of NAD+ compared to IV, although the effects are generally less immediate than with intravenous infusion.

• Cycle Length : Injectable NAD+ protocols typically consist of an intensive 4-8 week loading phase with administration 1-3 times per week, followed by a transition to maintenance with reduced frequency or a switch to oral NMN supplementation to sustain the elevated NAD+ levels achieved during the injectable phase. Injectable NAD+ can be considered a "reboot" tool that establishes a high baseline of cellular NAD+, which can then be maintained with more convenient and cost-effective oral precursors. For users with continuous access to and good tolerance of injectable NAD+, it can be used for a longer period with frequency adjustments based on response and goals, although most users find that after the initial loading phase, the benefits can be adequately maintained with oral precursors combined with occasional booster injections.

5-amino-1MQ

• Dosage : As an inhibitor of the NNMT enzyme that degrades NAD+, allowing NAD+ to accumulate within cells, a daily dose of 50–100 mg is recommended. The 50 mg dose is appropriate for most users and provides significant NNMT inhibition with a minimal side effect profile. Users seeking more pronounced effects on intracellular NAD+ bioavailability and activation of NAD+-dependent metabolic pathways may increase to 100 mg daily after assessing tolerance to the lower dose. Doses above 100 mg have not been extensively characterized and do not necessarily provide proportionate additional benefits.

• Administration frequency : 5-amino-1MQ is administered by subcutaneous injection once daily, preferably in the morning to take advantage of the period of greatest metabolic activity during daylight hours. The injection is typically well tolerated with minimal local irritation and should be administered at rotating sites to minimize any cumulative discomfort. Some protocols split the dose into two administrations of 25–50 mg each (morning and evening) to maintain more consistent NNMT inhibition throughout the day, although a single morning administration is generally sufficient and more convenient. Administration can be coordinated with other peptides requiring subcutaneous injection as part of the morning routine, using separate syringes and different injection sites.

• Cycle Duration : 5-amino-1MQ can be used continuously for 4-8 week cycles as an NAD+ bioavailability optimization phase, particularly when combined with NMN to create synergy where NMN provides substrate while 5-amino-1MQ prevents its degradation. After this initial cycle, a 2-4 week break is recommended to allow the NNMT enzyme to recover baseline function and to assess whether the benefits persist during the absence of the inhibitor. For long-term use, a cycle pattern of 6-8 weeks active followed by 2-4 weeks off, or intermittent use of 5 days per week with 2 days off, can be implemented. The synergy between 5-amino-1MQ and NMN is such that many users find they can use lower doses of NMN when combined with 5-amino-1MQ, which can be cost-effective while maintaining or even amplifying the effects on energy and mitochondrial function.

SIMPLIFIED ESSENTIAL PROTOCOL: A High-Impact Starting Point

For those looking to start with a more manageable protocol that addresses the fundamental elements with the greatest return on investment of effort and cost, the Essential Protocol includes five key compounds that can provide approximately 70-80% of the benefits of the full protocol:

Essential Stack of 5 Compounds

1. Ipamorelin (200-300 mcg, twice a day)

• Restores juvenile GH pulses
• Improves body composition and recovery
• Administer on an empty stomach in the morning and before bed

2. BPC-157 (250-500 mcg, 1-2 times a day)

• Reduces systemic inflammation
• Repairs intestinal permeability
• Administer subcutaneously, preferably abdominal area

3. DSIP (100-200 mcg, once a day)

• Restore the architecture of dreams
• Induces deep, restorative sleep
• Administer 30-60 minutes before bedtime

4. Enclomiphene (12.5-25 mg, every other day)

• Stimulates endogenous hormone production
• Improves libido, energy, and body composition
• Administer orally on alternate days

5. Kisspeptin-10 (100-150 mcg, once a day)

• Resets the HPG reproductive axis
• It facilitates the action of other compounds
• Administer in the morning on an empty stomach.

Implementation of the Essential Stack

Phase 1 (Weeks 1-2): Start with Ipamorelin, BPC-157 and DSIP only to establish a baseline of recovery and sleep.

Phase 2 (Weeks 3-4): Add Enclomiphene on alternate days, monitoring hormonal response.

Phase 3 (Weeks 5+): Incorporate Kisspeptin-10 to complete the essential stack and maximize synergy.

Total Essential Cycle Duration: 12-16 weeks of active use, followed by a 4-6 week break to reassess the need to continue.

This simplified protocol provides an accessible entry point that addresses the fundamental pillars: GH restoration, systemic repair, sleep optimization, endogenous hormonal stimulation, and reproductive axis reset. Additional compounds from phases 2-5 of the full protocol can be added later based on individual needs, tolerance, and response to the core stack.

IMPORTANT FINAL NOTES

Monitoring and Adjustments: All protocols should be implemented with careful attention to individual response. Maintaining a record of symptoms, perceived effects, and, where possible, relevant biochemical markers (hormones, glucose, lipids) allows for personalized optimization of dosage and timing.

Safety Considerations: These compounds represent advanced biooptimization tools. Although they have been used extensively in research and clinical settings with generally favorable safety profiles, their use should be informed and responsible. Individuals with pre-existing medical conditions, particularly those related to endocrine, metabolic, or cardiovascular function, should exercise additional caution.

Protocol Synergy: The power of this approach lies in its coordinated, multi-level attack. The compounds do not operate in isolation but in synergistic networks where each amplifies and facilitates the effects of the others. This is the fundamental difference between this systemic engineering protocol and conventional "symptom management" approaches that address isolated manifestations without correcting the underlying dysfunctions.

Beyond Compounds: No supplementation protocol, however advanced, can fully compensate for inadequate lifestyle fundamentals. Optimizing sleep, structured exercise (combining endurance and cardiovascular training), nutrient-dense nutrition, stress management, and intermittent calorie restriction are non-negotiable components that exponentially multiply the effects of any pharmacological intervention.

Menopause is not a sentence of inevitable decline. With the right knowledge, tools, and determination, it is possible not only to "manage" this transition but also to redesign one's biological trajectory toward one that preserves vitality, clarity, and functionality at levels that the conventional paradigm considers impossible. This protocol represents a roadmap to that possibility.